Incyte’s success with Jakafi® (ruxolitinihb) helped persuade MorphoSys that its tafasitamab (MOR208) could also be successfully commercialized by the Wilmington, DE, biopharma, which is licensing the B cell malignancy treatment candidate through a collaboration that could generate more than $2 billion for the German cancer drug developer . . .

Get GEN Edge Today!

The post Jakafi Success Helps Incyte Land Blockbuster MorphoSys Partnership appeared first on GEN – Genetic Engineering and Biotechnology News.